Key statistics
On Friday, Phaxiam Therapeutics SA (PHXM:PAR) closed at 1.59, 6.00% above its 52-week low of 1.50, set on Sep 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.72 |
---|---|
High | 1.72 |
Low | 1.57 |
Bid | 1.58 |
Offer | 1.69 |
Previous close | 1.72 |
Average volume | 23.25k |
---|---|
Shares outstanding | 10.01m |
Free float | 9.95m |
P/E (TTM) | -- |
Market cap | 17.22m EUR |
EPS (TTM) | -3.46 EUR |
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
- PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »
- PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
- PHAXIAM publie l’information financière du troisième trimestre 2024
- PHAXIAM Reports Third-Quarter 2024 Financial Information
- Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024
- PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis
- PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
- Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024
More ▼